GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Therapeutic Solutions International Inc (OTCPK:TSOI) » Definitions » Enterprise Value

Therapeutic Solutions International (Therapeutic Solutions International) Enterprise Value : $4.55 Mil (As of Jun. 10, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Therapeutic Solutions International Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Therapeutic Solutions International's Enterprise Value is $4.55 Mil. Therapeutic Solutions International's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.02 Mil. Therefore, Therapeutic Solutions International's EV-to-EBIT ratio for today is -2.25.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Therapeutic Solutions International's Enterprise Value is $4.55 Mil. Therapeutic Solutions International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.71 Mil. Therefore, Therapeutic Solutions International's EV-to-EBITDA ratio for today is -2.66.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Therapeutic Solutions International's Enterprise Value is $4.55 Mil. Therapeutic Solutions International's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.10 Mil. Therefore, Therapeutic Solutions International's EV-to-Revenue ratio for today is 46.39.


Therapeutic Solutions International Enterprise Value Historical Data

The historical data trend for Therapeutic Solutions International's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Therapeutic Solutions International Enterprise Value Chart

Therapeutic Solutions International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 15.17 68.03 16.93 4.82

Therapeutic Solutions International Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.62 7.35 6.66 4.82 5.70

Competitive Comparison of Therapeutic Solutions International's Enterprise Value

For the Biotechnology subindustry, Therapeutic Solutions International's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Therapeutic Solutions International's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Therapeutic Solutions International's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Therapeutic Solutions International's Enterprise Value falls into.



Therapeutic Solutions International Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Therapeutic Solutions International's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Therapeutic Solutions International's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Therapeutic Solutions International  (OTCPK:TSOI) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Therapeutic Solutions International's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=4.546/-2.018
=-2.25

Therapeutic Solutions International's current Enterprise Value is $4.55 Mil.
Therapeutic Solutions International's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.02 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Therapeutic Solutions International's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=4.546/-1.706
=-2.66

Therapeutic Solutions International's current Enterprise Value is $4.55 Mil.
Therapeutic Solutions International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.71 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Therapeutic Solutions International's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=4.546/0.098
=46.39

Therapeutic Solutions International's current Enterprise Value is $4.55 Mil.
Therapeutic Solutions International's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Therapeutic Solutions International Enterprise Value Related Terms

Thank you for viewing the detailed overview of Therapeutic Solutions International's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Therapeutic Solutions International (Therapeutic Solutions International) Business Description

Traded in Other Exchanges
N/A
Address
701 Wild Rose Lane, Elk City, ID, USA, 83525
Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for the development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).
Executives
Thomas Ichim director 211 E. OSBORN RD, PHOENIX AZ 85012
Gerry B Berg officer: CFO 1658 AVENIDA LA POSTA, ENCINITAS CA 92024
Timothy G Dixon director, officer: Chairman, President, CEO 4093 OCEANSIDE BLVD., SUITE B, OCEANSIDE CA 92056
Barry Glassman officer: VP, Training & Education 2051 ELBOW LANE, ALLENTOWN PA 18103
James P Boyd director, 10 percent owner PO BOX 2145, RANCHO SANTA FE CA 92067

Therapeutic Solutions International (Therapeutic Solutions International) Headlines

From GuruFocus